Chronic kidney disease is a major driver of morbidity in type 2 diabetes, and both SGLT2 and GLP2 receptor agonists are widely used for cardio renal risk reduction. However, comparative data on kidney specific outcomes remain limited.
Key evidence
A large real world comparative study published in JAMA Internal Medicine evaluated renal outcomes in patients with type 2 diabetes initiating either SGLT2 inhibitors or GLP1 receptor agonists. SGLT2 inhibitors use was associated with slower eGFR decline baseline albuminuria. The findings highlight class specific difference in renal disease progression.
Clinical or research implications
These results support preferential use of SGLT2 inhibitors for renal protection in high risk populations and may inform guideline recommendations and treatment sequencing in CKD management.